Cormorant Asset Management, LP Moon Lake Immunotherapeutics Transaction History
Cormorant Asset Management, LP
- $1.43 Billion
- Q3 2024
A detailed history of Cormorant Asset Management, LP transactions in Moon Lake Immunotherapeutics stock. As of the latest transaction made, Cormorant Asset Management, LP holds 8,494,151 shares of MLTX stock, worth $443 Million. This represents 30.01% of its overall portfolio holdings.
Number of Shares
8,494,151
Previous 8,494,151
-0.0%
Holding current value
$443 Million
Previous $373 Million
14.67%
% of portfolio
30.01%
Previous 28.74%
Shares
4 transactions
Others Institutions Holding MLTX
# of Institutions
124Shares Held
58.2MCall Options Held
52.2KPut Options Held
38K-
Bvf Inc San Francisco, CA21.8MShares$1.13 Billion34.86% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.98MShares$155 Million0.02% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.77MShares$145 Million2.1% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.32MShares$121 Million0.02% of portfolio
-
Holocene Advisors, LP New York, NY1.59MShares$82.7 Million0.35% of portfolio
About MoonLake Immunotherapeutics
- Ticker MLTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,925,600
- Market Cap $1.93B
- Description
- MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...